A regulatory requirement non interventional study to monitor the safety and effectiveness of JARDIANCE® (empagliflozin 10mg, 25mg) in Korean patients with type 2 diabetes mellitus (JARDIANCE® rPMS in Korean patients with T2DM)

31/05/2016
18/12/2025
EU PAS number:
EUPAS13627
Study
Finalised
Subscribe
Download as PDF
Documents
Study protocol
Updated protocol

1245-0116_Protocol_SAP_redacted.pdf

First published: 09/12/2025
English (574.63 KB - PDF) View document
Study results
Study results

1245-0116_Synopsis.pdf

English (458.09 KB - PDF) View document
Study report
Other information